Effects of sitagliptin beyond glycemic control: focus on quality of life

Abstract

BackgroundRecently, incretin hormones, including glucagon-like peptide-1 (GLP-1) analogue and dipeptidyl peptidase-4 (DPP-4) inhibitor, have been found to regulate glucose metabolism. The aim of this study was to elucidate the efficacy and safety of the clinical usage of DPP-4 inhibitors in Japan.MethodsThis study was designed as a prospective, open-label, multi-center trial. Patients with diabetes mellitus type 2 (T2DM) with poor glycemic profiles (HbA1c ≥ 6.2%) in spite of receiving a medical diet, therapeutic exercise, and/or medications were eligible for this study. The participants received 50 to 100 mg of the DPP-4 inhibitor sitagliptin once daily for 12 months.ResultsOne hundred and eighty-eight subjects were enrolled. After 12 months of sitagliptin treatment, HbA1c levels decreased (7.65% ± 1.32% to 7.05% ± 1.10%, p < 0.001) as well as fasting plasma glucose (FPG) (145 ± 52 mg/dl to 129 ± 43 mg/dl, p = 0.005). The rate of glycemic control achieved (in accordance with the guidelines of the Japanese Diabetes Society) significantly increased. Blood pressure and serum levels of triglycerides and total cholesterol decreased significantly. Furthermore, the Pittsburgh Sleep Quality Index (PSQI) and Diabetes Symptomatic Scores improved significantly. Adverse events such as hypoglycemia and loss of consciousness occurred in twenty three subjects (11%).ConclusionsThese results suggest that the actions of DPP-4 inhibitors improve not only glycemic control, but also blood pressure, lipid profiles, and quality of life (QOL). Sitagliptin is a sound agent for use in the comprehensive treatment of patients with T2DM.

Effect of L-Carnitine and/or Sitagliptin on Serum Lipids Profile of H2O2 Treated Rats (Part-1)

“…Beyond its glycemic control,DPP-4 inhibitors improve blood pressure, lipid profiles, and quality of life (QOL) in patients with T2DM (Kutoh and Yamashita, 2012;Sakamoto et al, 2013). Sitagliptin medication decreased serum levels of total cholesterol and triglyceride (Qin et al, 2005;Monamie et al, 2012;Picatoste et al, 2013).…”

Chronic Treatment with Novel GPR40 Agonists Improve Whole-Body Glucose Metabolism Based on the Glucose-Dependent Insulin Secretion

“…Sulfonylureas, dipeptidyl peptidase-IV (DPP-IV) inhibitors, and GLP-1 analogs are generally used as insulin secretagogues; however, sulfonylureas increase insulin secretion regardless of glucose level, thereby carrying the risk of promoting hypoglycemia and accelerating the exhaustion of pancreatic b-cells (Pfeifer et al, 1984;Melander et al, 1990), whereas DPP-IV inhibitors and GLP-1 analogs exhibit glucosedependent insulin secretion and carry a low risk of hypoglycemia (Herman et al, 2006;Engel et al, 2010;Bode, 2011). It is widely reported that long-term use of insulin secretagogues lead to reduction in blood hemoglobin A 1c (HbA 1c ) level in human (Charbonnel et al, 2013;Hanefeld et al, 2007;Sakamoto et al, 2013;Wang et al, 2011).…”

A CROSS SECTIONAL STUDY IN NORTH EASTERN UTTAR PRADESH POPULATION FOR THE ESTIMATION OF BMI, HDL & TRIGLYCERIDES LEVELS IN RECENTLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS TAKING METFORMIN ALONE, METFORMIN WITH ADD ON SITAGLIPTIN AND SITAGLIPTIN ALONE.

“…Other comparative studies reveal comparison of Lipid profiles include a study performed by Chawla S. et al [12] revealed a significant (p<0.01) decrease in High density lipoprotein (HDL-C) & a significant (p<0.01) decrease in Triglyceride, whereas Katsuyama et al [2] had also established that significant differences was seen in effects of Sitagliptin treatment on Another study performed by Sakamoto Y. et al [13] had demonstrated that serum levels of triglycerides and total cholesterol decreased significantly. (p<0.001).…”